Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation
- PMID: 8725045
- DOI: 10.1007/BF02552145
Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation
Abstract
Eighteen previously untreated patients with metastatic carcinoma of the prostate were treated with LHRH analogue. They were divided into 3 groups according to the degree of glandular differentiation. In all groups, a transient rise of PAP and PSA was observed after the LH and testosterone surge. However, relative values of LH, testosterone, PAP and PSA did not differ significantly among the 3 groups. These facts suggest that a transient rise of PAP and PSA is caused by testosterone surge independently from the degree of glandular differentiation after LHRH analogue administration in patients with advanced prostatic cancer.
Similar articles
-
Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate.Int Urol Nephrol. 1998;30(6):745-53. doi: 10.1007/BF02564863. Int Urol Nephrol. 1998. PMID: 10195870
-
Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.Urology. 1999 May;53(5):898-902; discussion 902-3. doi: 10.1016/s0090-4295(99)00061-8. Urology. 1999. PMID: 10223480 Clinical Trial.
-
Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.J Urol. 2005 Jul;174(1):140-2. doi: 10.1097/01.ju.0000161591.86721.e5. J Urol. 2005. PMID: 15947599 Clinical Trial.
-
[PSA progression under hormone therapy - of prognostic relevance?].Aktuelle Urol. 2012 Jul;43(4):262-4. doi: 10.1055/s-0032-1321735. Epub 2012 Aug 6. Aktuelle Urol. 2012. PMID: 22869497 Review. German.
-
Should we follow-up serum testosterone in patients with advanced prostate cancer?Expert Rev Anticancer Ther. 2010 Jul;10(7):1031-5. doi: 10.1586/era.10.92. Expert Rev Anticancer Ther. 2010. PMID: 20645692 Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous